GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (CHIX:DIAm) » Definitions » Institutional Ownership

Diasorin SpA (CHIX:DIAM) Institutional Ownership : 25.50% (As of Jun. 19, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Diasorin SpA Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Diasorin SpA's institutional ownership is 25.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Diasorin SpA's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Diasorin SpA's Float Percentage Of Total Shares Outstanding is 0.00%.


Diasorin SpA Institutional Ownership Historical Data

The historical data trend for Diasorin SpA's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA Institutional Ownership Chart

Diasorin SpA Historical Data

The historical data trend for Diasorin SpA can be seen below:

2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30 2025-05-31
Institutional Ownership 25.26 24.60 24.93 24.93 24.17 23.80 23.74 25.82 25.47 25.50

Diasorin SpA Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Diasorin SpA Business Description

Traded in Other Exchanges
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).

Diasorin SpA Headlines

No Headlines